Best-Value Biological Medicine: Tocilizumab

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of a best-value biological (BVB) medicine for tocilizumab.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting (PDF, size 471.1 KB, 2 pages) outlines the criteria that may be considered by the MMP in identifying the BVB medicine for tocilizumab.

Submissions are invited from all relevant stakeholders, and should be emailed to by 1pm on Monday 27 May 2024.